These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4102746)

  • 1. Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment.
    Van Sande M; Caers J; Lowenthal A
    Z Neurol; 1971 Apr; 199(1):24-9. PubMed ID: 4102746
    [No Abstract]   [Full Text] [Related]  

  • 2. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
    Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
    [No Abstract]   [Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa.
    Wilk S; Mones R
    J Neurochem; 1971 Sep; 18(9):1771-3. PubMed ID: 5571114
    [No Abstract]   [Full Text] [Related]  

  • 4. Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.
    Perschak H; Amsler U; Vischer A; Siegfried J; Cuénod M
    Hum Neurobiol; 1987; 6(3):191-4. PubMed ID: 2896652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders.
    Lakke JP; Teelken AW
    Neurology; 1976 May; 26(5):489-93. PubMed ID: 944400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ; Papadopoulos NM
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. II. Alterations of cerebrospinal fluid in patients with Parkinson's disease and chorea following the administration of alpha-methyldopa].
    Gründig E; Gerstenbrand F; Bruck J; Gnad H; Prosenz P; Simanyi M
    Dtsch Z Nervenheilkd; 1969; 196(3):256-65. PubMed ID: 5820717
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 9. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

  • 10. [Free amino acids in blood and cerebrospinal fluid in Parkinson's disease].
    TORRE M; SCARZELLA R; ZANALDA A
    Minerva Med; 1953 Jul; 44(59-60):256. PubMed ID: 13110848
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. I. Alterations of cerebrospinal fluid in patients with parkinson's disease and normals].
    Gründig E; Gerstenbrand F; Bruck J; Gnad H; Prosenz P; Teuflmayr R
    Dtsch Z Nervenheilkd; 1969; 196(3):236-65. PubMed ID: 5820716
    [No Abstract]   [Full Text] [Related]  

  • 12. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 13. Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease.
    Gjessing LR; Gjesdahl P; Dietrichson P; Presthus J
    Eur Neurol; 1974; 12(1):33-7. PubMed ID: 4413508
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B; Danta G; Schnieden H; Yuill GM
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):354-61. PubMed ID: 4714097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration.
    Tohgi H; Abe T; Hashiguchi K; Takahashi S; Nozaki Y; Kikuchi T
    Neurosci Lett; 1991 May; 126(2):155-8. PubMed ID: 1681472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebrospinal fluid proteins, amino acids and polypeptides in the differential diagnosis of strokes].
    Shvarev AI; Shtempel' AN; Tonkova NV; Pozdeev VK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976; 16(1):41-5. PubMed ID: 1258581
    [No Abstract]   [Full Text] [Related]  

  • 17. Isoelectric focusing and electrophoresis of the CSF proteins in tremor of different origins.
    Stibler H; Kjellin KG
    J Neurol Sci; 1976 Dec; 30(2-3):269-85. PubMed ID: 63543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)].
    Mazza C; Buffatti PF; Bazzan A; Lion P
    Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378
    [No Abstract]   [Full Text] [Related]  

  • 19. [Analysis of amino acids in the cerebrospinal fluid].
    Mashiko N
    Nihon Rinsho; 1973 May; 31(5):1029-37. PubMed ID: 4738411
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of dioxyphenylalanine (L-DOPA) on extrapyramidal motoric hyperkineses after prolonged neuroleptic therapy].
    Hippius H; Logemann G
    Arzneimittelforschung; 1970 Jul; 20(7):894-6. PubMed ID: 5536051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.